RecruitingPhase 3NCT06743646

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Studying Bietti crystalline dystrophy

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Chigenovo Co., Ltd
Principal Investigator: Jinlu Zhang, MD
Chigenovo Co., Ltd
Intervention: ZVS101e(drug)
Enrollment: 62 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2030

Study locations (8)

Peking University Third Hospital, Beijing, Beijing Municipality, China
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China
The First Affiliated Hospital of Harbin Medical University, Haerbin, Heilongjiang, China
Henan Provincial People's Hospital, Zhengzhou, Henan, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Tianjin Medical University Eye Hospital, Tianjin, Tianjin Municipality, China
Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06743646 on ClinicalTrials.gov

Other trials for Bietti crystalline dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Bietti crystalline dystrophy →

← Back to all trials